PFM Health Sciences LP Buys Shares of 368,929 Pulmonx Co. (NASDAQ:LUNG)

PFM Health Sciences LP purchased a new position in shares of Pulmonx Co. (NASDAQ:LUNG) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 368,929 shares of the company’s stock, valued at approximately $3,058,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in LUNG. FMR LLC grew its position in Pulmonx by 11.2% in the third quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after acquiring an additional 591,859 shares during the period. Millrace Asset Group Inc. acquired a new position in shares of Pulmonx in the 3rd quarter valued at $1,390,000. Squarepoint Ops LLC grew its holdings in shares of Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after purchasing an additional 104,432 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Pulmonx during the 2nd quarter worth $477,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Pulmonx by 7.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares during the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Trading Up 2.4 %

Shares of NASDAQ LUNG opened at $6.45 on Friday. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $254.71 million, a PE ratio of -4.39 and a beta of 0.68. Pulmonx Co. has a twelve month low of $5.46 and a twelve month high of $14.84. The stock has a fifty day simple moving average of $6.87 and a 200-day simple moving average of $7.05.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same quarter last year, the firm posted ($0.39) earnings per share. On average, equities analysts forecast that Pulmonx Co. will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

Separately, Stifel Nicolaus decreased their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Pulmonx presently has an average rating of “Moderate Buy” and an average price target of $14.67.

Insider Transactions at Pulmonx

In related news, General Counsel David Aaron Lehman sold 5,765 shares of Pulmonx stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total value of $38,567.85. Following the completion of the transaction, the general counsel now owns 203,348 shares in the company, valued at $1,360,398.12. The trade was a 2.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $8.09, for a total transaction of $161,800.00. Following the completion of the sale, the director now directly owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. This represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 70,351 shares of company stock valued at $494,094. 5.70% of the stock is currently owned by company insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.